SLC5A2 and hydrops fetalis: Our study is, to our knowledge, the first randomized controlled trial to specifically evaluate the incremental efficacy of adding sildenafil to a baseline regimen that already includes SGLT2 inhibitor therapy in patients diagnosed with HF and evidence of PH-LHD without needing an invasive test compared to dapagliflozin monotherapy.